Israel Biofund Gp Limited Partnership Orbimed serves as Executive at Novus Therapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Israel Biofund Gp Limited Partnership Orbimed has executed 15 insider transactions totaling $24.2M, demonstrating a bearish approach to their equity position. Their most recent transaction on Jan 3, 2023 involved selling 266,376 shares valued at $889.7K.
Israel Biofund Gp Limited Partnership Orbimed currently holds 2,311,798 shares of Novus Therapeutics, Inc. (NVUS), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Israel Biofund Gp Limited Partnership Orbimed has been a net seller of NVUS stock. They have purchased $2.1M and sold $22.1M worth of shares.
Israel Biofund Gp Limited Partnership Orbimed's most recent insider trade was on Jan 3, 2023, when they sold 266,376 shares at $3.34 per share.
Get notified when new Form 4 filings are submitted
| $4.51 |
| Discretionary |
| Jul 28, 2021 | PHGE | $0 | Purchase | 500,000 | $N/A | Discretionary |
| Jun 25, 2021 | NMTR | $19.3M | Sale | 15,989,876 | $1.21 | Discretionary |
| Jun 24, 2021 | NMTR | $440.6K | Sale | 319,255 | $1.38 | Discretionary |
| Jun 23, 2021 | NMTR | $1.1M | Sale | 841,650 | $1.36 | Discretionary |
| May 11, 2021 | NMTR | $8.8K | Exercise | 12,500 | $0.70 | Discretionary |
| May 11, 2021 | NMTR | $12.1K | Exercise | 19,444 | $0.62 | Discretionary |
| Oct 30, 2020 | NMTR | $0 | Other | 1,943,734 | $N/A | Discretionary |
| Jun 30, 2020 | NMTR | $0 | Conversion | 6,786,500 | $N/A | Discretionary |
| Apr 30, 2020 | NMTR | $0 | Award | 18,930,255 | $N/A | Discretionary |
| Dec 11, 2019 | PHGE | $48.2K | Purchase | 5,400 | $8.92 | Discretionary |
| Dec 10, 2019 | PHGE | $29.8K | Purchase | 3,400 | $8.75 | Discretionary |
| May 2, 2019 | NVUS | $2.0M | Purchase | 646,204 | $3.10 | Discretionary |
| May 9, 2017 | NVUS | $0 | Award | 2,537,110 | $N/A | Discretionary |